文献速递肿瘤 PET/CT

[68Ga]Ga-HER2-RGD双靶点分子探针用于乳腺癌PET/CT显像的实验研究

Experimental study of [68Ga]Ga-HER2-RGD, a dual-target molecular probe, for breast cancer PET/CT imaging.
PubMed 文献 · EJNMMI Res · 2026-06-09

本研究合成并评估了靶向HER2和整合素αvβ3的双靶点放射性配体[68Ga]Ga-DOTA-HER2-RGD,在三种乳腺癌细胞系及其荷瘤小鼠模型中进行体外和体内评价。该探针放化纯度>95%,IC50为12.9 nM,在MDA-MB-435 S(高HER2/高αvβ3)荷瘤中摄取最高,肿瘤/非肿瘤比值顺序为MDA-MB-435 S > MDA-MB-231 > MCF-7,阻断后摄取显著降低。结论认为该探针具有特异性双受体靶向特性,有望用于乳腺癌HER2和/或整合素αvβ3表达的无创可视化及半定量评估。

要点

  • [68Ga]Ga-HER2-RGD放化纯度>95%,IC50为12.9 nM,体外结合亲和力高。
  • 三种荷瘤模型肿瘤/非肿瘤比值:MDA-MB-435 S > MDA-MB-231 > MCF-7。
  • 阻断实验证实摄取可被过量未标记HER2-RGD显著降低,特异性良好。

核心结论

  • [68Ga]Ga-HER2-RGD具有针对HER2和整合素αvβ3的特异性双受体靶向特性,体外和体内研究均证实。
  • 该放射性肽有望作为新型PET显像剂用于乳腺癌HER2和/或整合素αvβ3表达的无创可视化,并能一定程度半定量评估其表达水平。

研究设计与样本

  • 合成并68Ga标记双靶点异二聚体放射性配体[68Ga]Ga-DOTA-HER2-RGD,评估放化纯度。
  • 使用三种乳腺癌细胞系MDA-MB-435 S(高HER2、高αvβ3)、MDA-MB-231(高HER2、低αvβ3)、MCF-7(低HER2、低αvβ3)及其各自荷瘤模型进行体外和体内评价。
  • 采用流式细胞术验证三种细胞表面HER2和整合素αvβ3表达谱,行体外细胞摄取、阻断和竞争结合实验,并行micro-PET/CT显像。

主要发现

  • 双靶点放射性肽成功合成并68Ga标记,放化纯度>95%。
  • 体外细胞研究显示MDA-MB-435 S摄取最高,其次为MDA-MB-231和MCF-7。
  • 竞争结合实验显示[68Ga]Ga-HER2-RGD高结合亲和力,IC50值为12.9 nM。
  • Micro-PET/CT显像显示[68Ga]Ga-HER2-RGD在MDA-MB-435 S荷瘤中显著聚集,非靶器官和组织摄取无或极低。
  • 三种荷瘤模型肿瘤/非肿瘤比值顺序为MDA-MB-435 S > MDA-MB-231 > MCF-7,与体外结果一致;给予阻断量HER2-RGD后MDA-MB-435 S荷瘤摄取显著降低。

关键数值与推荐

  • 放化纯度>95%。
  • IC50值为12.9 nM。
  • 肿瘤/非肿瘤比值顺序:MDA-MB-435 S > MDA-MB-231 > MCF-7。

临床怎么用

  • 该探针可在乳腺癌模型中无创可视化HER2和/或整合素αvβ3表达,并一定程度半定量评估表达水平。
  • 双靶点设计可能提高对HER2和/或整合素αvβ3过表达肿瘤的靶向结合与显像特异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiolabeled heterodimeric peptides have emerged as a highly promising targeting strategy for PET imaging due to their superior binding properties. The Human epidermal growth factor receptor 2 (HER2)- and Arg-Gly-Asp (RGD)-targeting moieties bind to HER2 and integrin αvβ3, respectively, receptors that are both overexpressed in many different types of tumors. This study focuses on the synthesis and evaluation of the heterodimeric radioligand [68Ga]Ga-DOTA-HER2-RGD for PET imaging of the breast cancers-bearing mouse models that overexpress HER2 and/or integrin αvβ3. RESULTS: The heterodimeric radiopeptide was successfully synthesized and radiolabeled with 68Ga, achieving a radiochemical purity of > 95%. The receptor-binding properties and tumor-targeting efficacy were evaluated in vitro and in vivo using three breast cancer cell lines-MDA-MB-435 S (high HER2, high αvβ3), MDA-MB-231 (high HER2, low αvβ3), and MCF-7 (low HER2, low αvβ3)-and their respective xenograft models. Flow cytometry verified the cell-surface expression profiles of HER2 and integrin αvβ3 in all three cell types. In vitro cell studies showed that the MDA-MB-435 S cell line exhibited the highest uptake of [68Ga]Ga-HER2-RGD, followed by MDA-MB-231 and MCF-7. High specificity was demonstrated in blocking studies using excess unlabeled HER2-RGD. Competitive binding assays revealed that [68Ga]Ga-HER2-RGD exhibited high binding affinity, with an IC50 value of 12.9 nM. Micro-PET/CT imaging revealed a significant accumulation of [68Ga]Ga-HER2-RGD in MDA-MB-435 S xenografts, with no or very low uptake in nontarget organs and tissues. Consistent with the in vitro findings, the tumor-to-nontumor ratios across the three xenograft models followed the order: MDA-MB-435 S > MDA-MB-231 > MCF-7. A significant decrease in [68Ga]Ga-HER2-RGD uptake in the MDA-MB-435 S xenografts was observed after the administration of blocking amount of HER2-RGD. CONCLUSION: [68Ga]Ga-HER2-RGD demonstrates specific dual-receptor-targeting properties towards HER2 and integrin αvβ3, as evidenced by in vitro and in vivo studies. This radiopeptide shows promise as a novel PET agent for the noninvasive visualization of HER2 and/or integrin αvβ3 expression in breast cancer, and is capable of semi-quantitatively evaluating the expression levels of HER2 and/or integrin αvβ3 to a certain extent.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Zhao X, Dai M, Li T, et al. Experimental study of [68Ga]Ga-HER2-RGD, a dual-target molecular probe, for breast cancer PET/CT imaging. EJNMMI Res. 2026. PMID: 42262467. doi:10.1186/s13550-026-01467-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。